To the Editor: We appreciate Dr. Yee's comments. As he points out, in the study published by Sullivan et al., the overall incidence of interstitial pneumonia due to all causes in CMV seropositive patients was significantly decreased by the administration of intravenous immune globulin (IVIG). Upon re-examination of the data presented, we find that the incidence of CMV pneumonia in seropositive patients who received IVIG was 10.9%, compared to an incidence of 14.9% in control patients. Although the difference in the incidence of CMV pneumonia was not significant, we still feel that the results of the study are encouraging. Results from further trials are necessary before a statement that IVIG definitely reduces CMV pneumonia can be made.

References